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j j Summary: A large evaluation study, analytical äs well äs clinical, was performed on four published improvements
ff for the determination of creatinine in serum. Two of the methods were based on the Jaffe reaction, the other two
were enzymatic methods.
Analytically, all four methods showed a similar performance. In the analysis of numerous specimens from advanced
care departments, however, the methods performed differently. The two enzymatic procedures scored better than
the two Jaffe methods, when compared with an HPLC-based reference method. However, even the best methods
produced outliers and a larger scatter than that obtained with "normal" specimens.
Introduction
In 1990 we initiated a study on the determination of
creatinine in serum because we questioned the overall
accuracy of our routine method (1). This study resulted
in cooperation with both the Bayer and the DuPont Com-
pany. Improvements in their Jaffe methods were pub-
lished (2, 3).
Later, we studied four commercial methods based on an
enzymatic reaction scheine. Special attention was paid
to interference by bilirubin (4).
We now raise the question ä;s to whether the current
creatinme determination is satisfactory. All these earlier
studies, döne separately, revealed one superior method,
although we always found outliers. Our däily routine
creatinine is run on ä Bayer-Technicon Chem-1 (two in-
struments) while our emergencies äre analysed with a
DuPont Dimension.
Both methods compare well, but we still encounter
Problems, especially with very ill patients that need ad-
vanced care.
Therefore we decided to initiate a study with a large
number of samples from our transplantation unit and
general surgery intensive care unit, including many ic-
teric specimens. We used the Chem-1 and the Dimen-
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sion, with the improved Jaffe methods, the best enzy-
matic method in our study, and a new enzymatic method
that was described recently (5).
The rationale was the fact that both the Chem-1 and the




The raw materials were the same äs described earlier (4).
Test Point unassayed chemistry controi serum level l and 2 were
from Technicon (Tarrytown, USA), and SRM 909a! and a2 Human
Serum were firom the National Institute of Standards and Technol-
ogy (Gaithersburg, USA).
For spiking of the albumin Solutions see Reference 4.
Methods
The current Chem-1 (called Chem-1, current) and Dimension
(called Dimension, DuPont) creatinine methods were applied äs
described by the manufacturers.
The Boehringer enzymatic creatinine method (called Dimension,
Boehringer) was modified äs described in our previous publication
(BM 3 4).
The Bayer enzymatic creatinine method (called Dimension, Bayer)
was introduced äs a Dimension open channel procedurc according
to the following assay conditions:
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The chemistry of this method has been described by Fossati et al.
(5). The reagents, Sera-Pak creatinine UV Method No. 6592, were
provided by^Bayer and are not yet available for commercial use.
As a reference method we used our HPLC prqcedure (6).
son method was used s a reference method. All samples
were analysed in duplicate.
Analytical performance
The performance was studied by measuring imprecision,
linearity, recovery of 30 different commercial samples
and the interference of bilirubin-enriched artificial sam-
ples.
Imprecision
As mentioned in Materials and Methods, all results were
obtained by using the SRM 909a values s calibrator
points. Every ran incl ded both levels. The results mea*
sured were also used for calcul tion of the between-run
coefficient of Variation. In table l these data are given.
We found compar ble results for the boviiie control sam-
ples (Test Point unassayed samples).
Patient samples
Serum specimens used in this study were collected in various de-
partments in the University Hospital Rotterdam. All samples were
stored at —70 °C prior to use.
The icteric samples showed a total bilirubin concentration ranging
from 79 to 886 μηιοΐ/ΐ. The transplantation sera came from patients
after kidney, heart or liver transplantation. Samples from our sur-
gery intensive care unit were not selected according to any crite-
rion, except intensive care.
Statistical analysis
Regression analysis was done according to Passing & Bablok (7).
Between-run Variation was calculated using Test Point unassayed
chemistry control serum level l (± 93 μιηοΐ/l in our daily routine)
and level 2 (± 665 μηιοΐ/ΐ in our routine) and both SRM samples
(concentrations 84 and 463 μιηοΐ/ΐ respectively).
Linearity
We applied two approaches for the measurement of the
linearity of patient samples and albumin Standards. For
the patient samples, the highest value used was 1329
μηιοΐ/ΐ (HPLC value) while the albumin Standards
ranged up to 1985 μπιοΐ/ΐ (HPLC value).
In table 2 all Information is tabulated.
Only the Bayer method declined slightly at levels higher
than 1300 μιηοΐ/ΐ. This was coiifirmed with the albumin
Standards, and the highest concentration (1985 μηιοΐ/ΐ)
resulted in a value of 1929 μπιοΐ/ΐ.
Instrumentation
Both the Chem-1 and Dimension were used according to the manu-
facturer's instructions. For the calibration we followed the Techni-
con procedure for the Chem-1. The current Dimension was corre-
lated precisely with the Chem-1, using patient samples.
Both enzymatic procedures were calibrated with the SRM 909
samples.
All methods were checked for accuracy during all runs with the
same SRM 909 samples.
The recovery study was designed s a commutability study with
samples used in the quality control schemes of the Dutch Quality
Assessment Foundation (SKZL).
Results
The study consisted of an analytical part and a clinical
evaluation. Most of the time our HPLC-based compari-
Tab. l Imprecision methods.
Between-run Variation for samples SRM 909ai and a2 (stated val-
ues 84 and 463 μηιοΐ/ΐ).
Method SRM909a, SRM909ai'
Creatinine CV Creatinine CV
(μηιο1/1) (%) (μπϊοΐ/ΐ) (%)
Chem-1 , current 8 1 .6 6.2 469
(π = 9)
Dimension, DuPont 81.6 4.5 465
(n = 9)
Dimension, Boehringer 84.7 4.5 462
(n = 9)
Dimension, Bayer 88.7 1.5 460
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Tab. 2 Patient samples (50) ranging 28-1329 μιηοΐ/ΐ. Albumin










y = l.lOx - 2
y * 1.02x - l
y = l.Olx + 3
y » 0.98x + 7
y = l.06x - 23
y = 0.96x - 16
y = 1.06x - 10
y = 0.98x H- 7
χ = HPLC-method
y = method undcr study
Recoveiy
We only used those commercial samples with creatinine
values lower than 300 μιηοΐ/ΐ. All the results are shown
in figure 1.
Bilirubin interference
Interference by conjugated and unconjugated bilirubin
in a human albumin based creatinine Standard was in-
vestigated for all the methods under study. The results
are shown in figures 2 and 3.
Total bilirubin concentrations were measured with the
Chem-1 method according to the instructions of the
manufacturer.
Clinical evaluation
In the clinical part of the study we analysed 388 samples
frorn 312 patients. There were roughly equal numbers
of samples frorn icteric patients, transplanted patients
and intensive care patients.
It was possible to trace the samples, if more clinical
Information was required.
In the graphs we restricted urselves to creatinine values
lower than 300 μπιοΐ/ΐ. All methods were studied with
roughly the same number of equal samples, with the
exception of the Bayer method, the study of which was
started at a later stage. At the time, it was most conve-
nient for us to use only the Dimension s- die analysing
instrumerit. Later, we will also evaluate the Chem-1, s
we are in the process of adapting the Bayer method to
this instrument.
Samples from icteric patients
To present a single impression of an x^y-diagram for
each of the various method comparisons, all results of
the determmations with the icteric specimens are de-








































Fig. l Comparison of methods under study (y-axis) and our
HPLC based reference method (x-axis) using 30 different commer-
cial control sera:
a) Chem-1, current method
b) Dimension, DuPont method
c) Dimension, Boehringer method
d) Dimension, Bayer method
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More detailed Information can be obtained from figures
5, where we plotted the residuals versus the creatinine
levels, and from figure 6, where we did the same versus
the bilirubin concentrations.
Samplesfrom transplanted patients
Here, only the residuals versus the creatinine concentra-
tions are plotted (see flg. 7).
Samplesfrom intensive care patients
The same choice was made for these samples, i. e. only
the results of the residuals are plotted (see fig. 8).
Discussion
As we stated in the Introduction, much effort has been





Fig. 2 The influence of unconjugated bilirubin (added s biliru-
bin-enriched albumin Solutions) on methods under study:
O = Chem-1, current method
Π = Dimension, DuPont method
O = Dimension, Boehringer method









Fig. 3 The influence of ditaurobilirubin (added s ditaurobili^
rubin-enriched albumin Solutions) on methods under study:
O = Chem-1, current method
α = Dimension, DuPont method
O = Dimension, Boehringer method


































Fig. 4 Comparison of methods under study (y-axis) and our
HPLC based reference method (x-axis) using icteric patient sam^
ples:
a) Chern-1, current method
b) Dimension, DuPont method
c) Dimension, Boehringer method
d) Dimension, Bayer method
TThe circied points fefer to samples containing 5-fiuoro racil (see
Discussion). v ?
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Fig. 5 Residual creatinine vahies of icteric sera plotted against
the creatinine (HPLC) concentration for the methods under study:
a) Chem-1, current jnethod
b) Dimension, DuPont method
c) Dimension, Boehringer method
d) Dimension, Bayer method
Fig. 6 Residual creatinine values of icteric sera plotted against
the bilirubin concentration for the methods under study:
a) Chem-1, current method
b) Dimension, DuPont method
c) Dimension, Boehringer method
d) Dimension, Bayer method
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Fig. 7 Residual creatinine values of transplanted patients' sam-
ples plotted against the creatinine (HPLC) concentration for the
methods under study:
a) Chem-1, current method
b) Dimension, DuPont method
c) Dimension, Boehringer method
d) Dimension, Bayer method
Creatinine (HPLC) [/imol/l]
Fig. 8 Residual creatinine values of intensive care patients' sam*
ples plotted against the creatinine (HPLC) c ricentration for the
methods hdef study:
a) Chem-1, current method
b) Dimension,, DuPont method
c) Dimension, Boehringer method
d) Dimension, Bayer method
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determination of creatinine in serum. Although the creat-
inine determination in clinical practice is nearly 100
years old (8), there still is much debate regarding its
accuracy (9). Numerous articles have been written on
modifications and improvements of the various reaction
principles, be it the Jaffe reaction or an enzymatic pro-
cedure.
We have also added to this long list of publications, for
the same reason: dissatisfaction with the existing pro-
cedures. We cooperated with some manufacturers on
their method modifications, and we were able to publish
improvements, without being sure that we had achieved
absolute accuracy. The same held true for our own modi-
fications of some enzymatic methods.
Knowing that we had now reached the state-of-the-art
with the above-mentioned manufacturers, we wanted to
make a choice for ourselves. Therefore we organized a
large study, which was analytical s well s clinical.
As mentioned earlier, we use two Chem-1 Systems in our
routine section, and a Dimension for our emergencies.
Correlation of the creatinine determinations on these in-
struments occupies much of our attention, in view of
the plausibility study of our quality control scheme. The
numerous drugs, in particular to the many advanced care
patients in our large hospital, sometimes give rise to sig-
nificant differences in the results obtained with the
Chem-1 and the Dimension, despite the perfect correla-
tion nonnally seen.
In order to complete the statistical evaluation, all regres-
sipn characteristics are given in table 3.
Considering all Information in the figures and men-
tioned in table 3, we feel that both enzymatic procedures
score better than both Jaffe methods. The performances
of the two enzymatic methods are more or less compara-
ble, while the two Jaffe methods show certain differ-
ences, the Chem-1 modification generally showing a
worse performance. It is not possible to compare our
Boehringer modification and the Bayer method com-
pletely, because the number of samples differ.
At the time of inclusion of the Bayer method, the
number of icteric samples was becoming depleted (98
versus 123). It is just this section where the Boehringer
method scatters more than the Bayer method (fig. 5c and
5d). Here the Bayer method graph shows two interesting
results, which were traced to one patient with metasta-
sized breast carcinoma, receiving a number of drugs at
the time the samples were taken. These drugs included
5-fluorouracil which has the same type of molecular
structure s 5-fluorocytosine, which was listed by Fos-
sati et al. (5) s an in vitro interferent.
With respect to bilirubin interference, in vitro and in
vivo (figs. 2, 3, 6c and 6d), the Bayer method scores
better in the higher bilirubin r nge (> 400 μιηοΐ/ΐ). On
the other hand, the linearity study suggests that the
Boehringer method may be somewhat better than the
Bayer method. Fossati et al. found a better linearity (up
till 1768 μιηοΐ/l). In the daily clinical Situation, however,
the linearity of both methods is quite acceptable.
Both the current Chem-1 and the Dimension methods
are based on the Jaffe reaction. There is one striking
Tab. 3 Statistical evaluation.


































y = l.llx - 3; r = 1.00; n = 46
y = l.lSx - 28; r = 0.99; n = 132
y = 1.07x + 4;r = 0.99; n = 104
y = 1.14x - 12; r = 0.99; n = 98
y = 1.03x - l ;r = 1.00; n = 46
y = l.OSx + 4; r = 1.00; n = 140
y = 1.02x -1- 19; r = 1.00; n = 130
y = 1.07x- l ; r = 0.97; n = 92
y = 1.03x- l ; r = 1.00; n = 46
y = 0.96x + 7; r = 1.00; n = 140
y = 1.03x + 2; r = 1.00; n = 130
y = 1.05x; r = 1.00; n = 100
y = 0.98x + 8; r =1.00; n = 46
y = l.OOx + 11; r = 1.00; n = 111
y = l.Olx + 7;r = 1.00; n = 128
y = 1.02x + 8 ; r = 1.00; n = 100
x = HPLC-method
y = method under study
"Normar = non-icteric, non-haeraolytic and non-lipaemic
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difference regarding the correction for the bilirubin in-
terference. The Chem-1 uses a selective bichromatic
measurement for icteric samples while in the Dimension
formulation bilirubin is oxidised by potassium hexacya-
noferrate(III). The in vitro experiments with bilirubin-
enriched samples show an acceptable performance for
both methods (figs. 2 and 3) while the icteric patient
samples give a larger scatter, especially with the Chem-
1 (figs. 4a, 4b, 5a and 5b).
This may mean that oxidation of bilirubin is a better
way of circumventing the interference than the use of a
mathematical algorithm. We have no experience of, and
are not aware of any detailed literature on this question
(10, 11). The experiments with specimens frorn trans-
planted patients confirm that the kinetics of the Jaffa
reaction probably also contribute to the differences in
the results of the two methods. We observed no abnor-
mal colouring of the samples, which had been submitted
for cyclosporin assays. However, it is certain that many
more drugs\were involved.
It may also be helpful to compare the results presented
in the residual graphs for the pathological specimens (ic-
teric, transplantation and intensive care) with those ob-
tained with "normal" serum samples. Here, normal is
defined s non-icteric, non-haemolytic and non-lipae-
mic. In figure 9, only the data related to the Bayer
method are given s an example of the observed scatter.
The other methods show a comparable picture.
The Variation with pathological sera is higher than with
"normal" sera for all methods. Especially in the clini-
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Fig. 9 Residual creatinine values of "normal" sera plotted against
the creatinine (HPLC) concentration for the Dimension, Bayer
method.
room for an improvernent of accuracy, although it is
clear that the two enzymatic methods perform better
than the Jqffe-basea methods.
An overall picture of all residual graphs shows a calibra-
tion problem. All measurernents were done within a few
weeks and where possible grouped together according
to the nature of the samples. Differences are particularly
apparent in the Chem-1 results: the average residual is
negative for icteric specimens, positive for transplanta-
tion specimens and ab t zero for intensive care sam*
ples. The most positive picture is sfoown by another
Bayer developmentj i. e. the Bayer enzymatic procedure.
An interesting Situation is revealed in the graphs of the
commercial samples (flg. 1), and this clearly reflects the
Problems we meet in assessing surveys. We had the
same experience last year in the Netherlands and earlier
in Germany. Thus, application of reference methodology
(the correct way) may lead sometimes to difficulties in
Interpretation with particular tests. Here too, it has to be
emphasized that both Jaffa methods perform less well
than the enzymatic methods.
In the Introduction we raised the question: are we satis-
fied with the improvements? We are sure that we can
improve our daily Situation iii theory. The least we can
do, considering that both the Chem^l and the Dimension
can now be used s open Systems, is to tiy to use a
single method. From our ranking, it is clear that we have
to replace the current Chem-1 method. At the moment
we have no practical experience to support this move,
but this and the financial implications must be faced,
especially regarding the introduction of enzymatic pro-
cedures. There is one practical limitation, i. e. the Bayer
method is not yet commercialized.
Finally, we are not entirely negative regarding our cmr-
rent Chem-1 method. We have been running this method
for almost one year, and it performs well for the majority
of specimens, s shown by our quality control scheme,
s well s all studies we have performed. Nevertheless,
it is clear that we can do better, and that is also our wish.
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